Does sequestering actin suppress the cytoskeleton?

No. It maintains a controlled reservoir. Unbound monomer above a critical concentration polymerises spontaneously; holding it bound keeps it available for assembly where the cell chooses.

Does TB-500 bind filaments?

The target is monomeric G-actin, not filamentous F-actin.

Is this established for the fragment or the protein?

Well established for the protein. The fragment carries the associated motif, which is why this activity transfers most defensibly.

Actin Sequestration: The TB-500 Mechanism

The short answer

Thymosin beta-4 is the principal G-actin sequestering protein in many cell types: it binds actin monomers and holds them unpolymerised, maintaining a reservoir that can be released for rapid filament assembly. TB-500 carries the motif associated with that binding.

Key facts

Target: G-actin (monomeric actin)
Effect: Prevents incorporation into filaments
Purpose: Maintains a monomer reservoir
Tβ4 role: Principal sequestering protein in many cells
F-actin: Filamentous form (not the target)
Evidence: Well established for the protein

Two forms of actin

Actin exists as free monomers, G-actin, and as polymerised filaments, F-actin. The cytoskeleton is built from filaments, and cells constantly build and dismantle them, for movement, division, and changing shape. The rate at which a cell can do this depends on how much monomer is available to polymerise.

Why a cell would hold monomers back

This is the counterintuitive part. Sequestering actin sounds like suppressing the cytoskeleton, and it is closer to the opposite. Free G-actin above a critical concentration polymerises spontaneously and uncontrollably. Holding a large monomer pool bound keeps it out of filaments while keeping it immediately available, so the cell can assemble filaments quickly, where it chooses, rather than having actin polymerise everywhere at once.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The reservoir analogy

A sequestering protein functions like a dam rather than a drain. The stored monomer is not discarded; it is held under control and released on demand. This is why thymosin beta-4 is described as enabling rapid cytoskeletal remodelling despite its immediate action being inhibitory.

How this connects to the reported effects

Cell migration requires continual cytoskeletal reorganisation, filaments assembling at the leading edge and disassembling behind. Anything altering monomer availability plausibly affects that process, which is the mechanistic bridge between actin sequestration and the migration and repair literature. The bridge is coherent; it is not the same as demonstrated in the systems where repair was observed.

What applies to the fragment

Actin sequestration is well established for full-length thymosin beta-4. TB-500 carries the motif associated with it, and this is the activity that transfers to the fragment most defensibly. Effects further downstream, migration, angiogenesis, repair,were largely characterised with the protein.

Frequently asked questions

Does sequestering actin suppress the cytoskeleton?: No. It maintains a controlled reservoir. Unbound monomer above a critical concentration polymerises spontaneously; holding it bound keeps it available for assembly where the cell chooses.
Does TB-500 bind filaments?: The target is monomeric G-actin, not filamentous F-actin.
Is this established for the fragment or the protein?: Well established for the protein. The fragment carries the associated motif, which is why this activity transfers most defensibly.

Extended research context

The TB-500 (Thymosin β4 fragment) deep dive

Deep dive: TB-500 vs full-length Thymosin Beta-4

'TB-500' is a synthetic peptide corresponding to the active 17-amino-acid actin-binding region of the endogenous 43-residue Thymosin Beta-4 protein. The two are not identical. TB-500 lacks the flanking sequence that gives full-length TB-4 additional binding partners. In the research literature, papers use 'Thymosin β4' when they mean the full protein and 'TB-500' or 'AcSDKP fragment' when they mean the shorter synthetic peptide. Reading a CoA carefully to see which molecule is in the vial matters. Mass spec is the definitive check.

Actin-binding as the core mechanism

The N-terminal region of TB-4 (and TB-500 by inheritance) contains the canonical actin-binding motif. This motif sequesters G-actin monomers, modulating the G:F actin equilibrium in cell cultures. That mechanism is why almost every mechanistic paper on TB-500 traces back to cytoskeletal reorganisation, cell migration, and models of tissue repair.

Handling considerations unique to TB-500

TB-500 is a 17-residue peptide with modest amphipathicity; it reconstitutes cleanly in bacteriostatic water but is sensitive to repeated freeze/thaw. Aliquoting into single-use volumes on first reconstitution preserves potency across a batch. HPLC on the batch CoA should show a single dominant peak; a doublet suggests deamidation.

Research applications

▸In vitro actin-polymerisation assays (G:F actin ratio measurement)
▸Cell-migration and wound-scratch assays in fibroblast lines
▸Angiogenesis models: tube-formation and endothelial migration assays
▸Analytical method development for short peptides on RP-HPLC
▸Reference-material comparisons against endogenous Thymosin β4

Handling checklist

✓Store lyophilised vials at −20 °C long-term
✓Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
✓Aliquot immediately to avoid freeze/thaw cycles
✓Refrigerate reconstituted aliquots at 2–8 °C; use within 28 days
✓Confirm mass (~4,963 Da for TB-500) via CoA before study use

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Assuming TB-500 = full Thymosin β4

Fix: TB-500 is the 17-residue actin-binding fragment; check the CoA sequence.

✗ Repeated freeze/thaw

Fix: Aliquot at first reconstitution; each cycle degrades yield.

✗ Using tap water

Fix: Use bacteriostatic or sterile water only.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More TB-500 (Thymosin β4 fragment) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

How Actin Sequestration Works